News & Events

eBioscience Collaborates with Leading Age Research Institute to Develop Novel Stem Cell Reagents

San Diego and Novato, CA/December 4, 2009 - eBioscience Corporation today announced a multi-year strategic collaboration with the Buck Institute for Age Research, one of the world's foremost and well respected biomedical research institutes, to develop and commercialize a diverse array of unique and proprietary stem cell reagents for use in flow cytometry, immunodetection, microscopy and in-vivo imaging. The collaboration will enable eBioscience to combine its robust reagent development capabilities and broad menu of proprietary fluorescent eFluor® dyes with the Buck Institute's expertise in stem cell discovery, characterization and analysis. The collaboration entails know-how exchange, research funding, and other undisclosed financial terms. eBioscience will have exclusive research rights to the reagents generated through the collaboration and the Buck Institute will have broad access to those reagents to further its stem cell research studies.

"We are very fortunate to be able to collaborate with one of the world's leading experts in stem cell biology to develop innovative, proprietary stem cell research reagents for the cellular analysis market," commented eBioscience CEO, Todd R. Nelson Ph.D. "The scientific and medical expertise the Buck Institute brings to the collaboration, when combined with our own internal core competencies in reagent development and product commercialization, will allow us to continue to fulfill eBioscience's goal of being first to market with innovative, proprietary reagents. This project further demonstrates our commitment to stem cell research, one of the fastest growing areas in biology. Importantly, for researchers worldwide, this collaboration should provide additional access to a significant number of novel, cutting-edge tools and technologies necessary to advance the understanding of stem cells and their roles in both normal and disease biology."

"This agreement is a perfect fit with our ongoing stem cell research program," said Remy Gross, the Buck Institute's Director of Business Development. "The funding will support Buck Institute scientists focused on the differentiation of stem cells; our identification of novel tools and reagents will enable eBioscience to make them available to advance stem cell science around the world."

About eBioscience Corporation

eBioscience provides innovative high quality reagents to academic and government researchers and pharmaceutical and biotech companies worldwide that empower the process of scientific discovery in the areas of cellular immunity and oncology. The company's extensive portfolio of more than 10,000 leading edge cell analysis reagents and technologies, focused on flow cytometry and immunodetection, position our customers to be at the forefront of science. eBioscience is aligned with, and responsive to, the ever changing needs of its customers, making the company a preferred partner for scientific discovery. Founded in 1999, eBioscience is headquartered in San Diego, California and conducts business in more than 70 countries around the world. For more information about eBioscience, visit the company's website at www.eBioscience.com

About Buck Institute of Age Research

The Buck Institute is the only freestanding institute in the United States that is devoted solely to basic research on aging and age-associated disease. The Institute is an independent nonprofit organization dedicated to extending the health span, the healthy years of each individual's life. The National Institute on Aging designated the Buck Institute a "Nathan Shock Center of Excellence in the Biology of Aging," one of just five centers in the country. Buck Institute scientists work in an innovative, interdisciplinary setting to understand the mechanisms of aging and to discover new ways of detecting, preventing and treating conditions such as Alzheimer's and Parkinson's disease, cancer, diabetes and stroke. Collaborative research at the Institute is supported by new developments in genomics, proteomics, stem cell, and bioinformatics technology. For more information: www.buckinstitute.org

eBioscience contact:
Dan St Louis, Ph.D.
Vice President, Research & Development
858-784-5035
dan.stlouis@eBioscience.com

Buck Institute contact:
Kris Rebillot
Public Information Officer
415-209-2080
krebillot@buckinstitute.org